Skip to content

To evaluate the efficacy of Ashokavalkalaksheerpaka in the management of Asrigdara

A clinical study to evaluate the efficacy of Ashokavalkalaksheerpaka in the management of Asrigdara - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084683
Enrollment
30
Registered
2025-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N921- Excessive and frequent menstruation with irregular cycle

Interventions

None listed

Sponsors

Government Ayurvedic college and hospital Kadamkuan Budhamurti patna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients willing for trial 2 patients of age group 15 to 45 years 3 Clinical symptoms of Asrigdara 4 Patients of having any of symptoms Excessive bleeding per vagina (amount more than 80 ml) Prolonged bleeding per vagina (with the duration of more than 7 days) 5 Hb percentage more than equal to 8 gm per dl

Exclusion criteria

Exclusion criteria: 1 Pregnant woman 2 Benign & Malignant growth in uterus 3 Ectopic pregnancy 4 Patients having bleeding due to abortion 5 Patients using IUCD, OCP 6 Patient with systemic disorders interfering with the present study 7 Coagulation disorders 8 Patient have been suffering from sexually transmitted diseases like AIDS, Syphilis etc 9 Bleeding sites other than the uterus 10 Uterine and pelvic pathology like Endometrial T.B , Adenomyosis, PID, Polyps etc.

Design outcomes

Primary

MeasureTime frame
Relief from sign and symptomsTimepoint: 2 months

Secondary

MeasureTime frame
Determination of effect of intervention w.r.t otherTimepoint: 2 months

Countries

India

Contacts

Public ContactDr Neelam kumari

Government Ayurvedic College Kadamkuan Patna

dr.prabhapandey@yahoo.in7004860634

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026